Correction to: *Scientific Reports* 10.1038/s41598-020-60437-0, published online 27 February 2020

This Article contains a typographical error in the Introduction where the following is repeated twice:

"A single response profile, such as pseudo-progression, is observed under CPIs^7^. Among these typically-related response profiles under CPIs is hyperprogressive disease (HPD), which was defined as an unanticipated and paradoxical acceleration of the tumor growth^7,8^. The incidence of HPD is variable according to the way it is defined and ranges between 4 and 29%^7^. Though such acceleration of the tumor growth kinetic was also observed with other agents (chemotherapy^9^, tyrosine kinase inhibitors^10^), the intensity and the frequency of the phenomenon appears to be higher with checkpoint inhibitors used alone^7^."

Additionally, Table 4 contains an error where the labels for 'Risk Group' and 'Hyperprogressive Disease' are swapped. The correct Table [4](#Tab1){ref-type="table"} appears below.Table 4.Hyperprogressive diseaseTotal n (%)Risk GroupOdds Ratio (CI 95%)pLow riskHigh riskNo HPD69 (86.25%)66 (95.5%)3 (4.5%)1.0 referentHPD11 (13.75%)6 (54.5%)5 (45.5%)18.34 \[3.38--99.58\]\<0.001
